Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Key result
Empagliflozin cuts CV death or heart failure hospitalization in HFpEF regardless of diabetes status.
Why the study?
Does empagliflozin reduce the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction?
Population
Patients with heart failure and a preserved ejection fraction, with or without diabetes
Authors
Discussion
Loading...
Member takes
Implication
Supports empagliflozin initiation in HFpEF irrespective of diabetes; extends SGLT2i benefits to preserved ejection fraction.
Key Points
- To evaluate the impact of empagliflozin on cardiovascular outcomes in heart failure with preserved ejection fraction.
- Clinical trial design
- Included patients with heart failure and preserved ejection fraction
- Assessed combined risk of cardiovascular death and hospitalization for heart failure
- Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for heart failure
- Effects observed regardless of diabetes status
Structured PICO
Does empagliflozin reduce the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction?
P
Population
Patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes
I
Intervention
Empagliflozin
O
Outcome
Combined risk of cardiovascular death or hospitalization for heart failurecomposite
Empagliflozin reduces the composite risk of cardiovascular death or heart failure hospitalization in patients with HFpEF, independent of diabetes status.
Cite This Study
Anker et al. (2021) studied this question. Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with preserved ejection fraction, regardless of diabetes status.